Literature DB >> 15860577

Studies of the biogenic amine transporters. XI. Identification of a 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909) analog that allosterically modulates the serotonin transporter.

Barbara Nightingale1, Christina M Dersch, Terrence L Boos, Elisabeth Greiner, William J Calhoun, Arthur E Jacobson, Kenner C Rice, Richard B Rothman.   

Abstract

Previous studies identified partial inhibitors of serotonin (5-HT) transporter and dopamine transporter binding. We report here on a partial inhibitor of 5-HT transporter (SERT) binding identified among a group of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine analogs (4-[2-[bis(4-fluorophenyl)-methoxy]ethyl]-1-(2-trifluoromethyl-benzyl)-piperidine; TB-1-099). Membranes were prepared from rat brains or human embryonic kidney cells expressing the cloned human dopamine (hDAT), serotonin (hSERT), and norepinephrine (hNET) transporters. beta-(4'-(125)Iodophenyl)tropan-2beta-carboxylic acid methyl ester ([(125)I]RTI-55) binding and other assays followed published procedures. Using rat brain membranes, TB-1-099 weakly inhibited DAT binding (K(i) = 439 nM), was inactive at NET binding ([(3)H]nisoxetine), and partially inhibited SERT binding with an extrapolated plateau ("A" value) of 20%. Similarly, TB-1-099 partially inhibited [(125)I]RTI-55 binding to hSERT with an extrapolated plateau (A value) of 14%. Upon examining the effect of increasing concentrations of TB-1-099 on the apparent K(d) and B(max) of [(125)I]RTI-55 binding to hSERT, we found that TB-1-099 decreased the B(max) in a dose-dependent manner and affected the apparent K(d) in a manner well described by a sigmoid dose-response curve. TB-1-099 increased the K(d) but not to the magnitude expected for a competitive inhibitor. In rat brain synaptosomes, TB-1-099 noncompetitively inhibited [(3)H]5-HT, but not [(3)H]dopamine, uptake. Dissociation experiments indicated that TB-1-099 promoted the rapid dissociation of a small component of [(125)I]RTI-55 binding to hSERT. Association experiments demonstrated that TB-1-099 slowed [(125)I]RTI-55 binding to hSERT in a manner unlike that of the competitive inhibitor indatraline. Viewed collectively, these results support the hypothesis that TB-1-099 allosterically modulates hSERT binding and function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15860577     DOI: 10.1124/jpet.105.084376

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters.

Authors:  Richard B Rothman; John S Partilla; Michael H Baumann; Catrissa Lightfoot-Siordia; Bruce E Blough
Journal:  J Pharmacol Exp Ther       Date:  2012-01-23       Impact factor: 4.030

2.  Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release.

Authors:  Joseph J Pariser; John S Partilla; Christina M Dersch; Subramaniam Ananthan; Richard B Rothman
Journal:  J Pharmacol Exp Ther       Date:  2008-04-25       Impact factor: 4.030

3.  Studies of the biogenic amine transporters 15. Identification of novel allosteric dopamine transporter ligands with nanomolar potency.

Authors:  Richard B Rothman; Subramaniam Ananthan; John S Partilla; Surendra K Saini; Omar Moukha-Chafiq; Vibha Pathak; Michael H Baumann
Journal:  J Pharmacol Exp Ther       Date:  2015-03-18       Impact factor: 4.030

4.  Structure-activity relationship studies of citalopram derivatives: examining substituents conferring selectivity for the allosteric site in the 5-HT transporter.

Authors:  M Andreas B Larsen; Per Plenge; Jacob Andersen; Jonas N N Eildal; Anders S Kristensen; Klaus P Bøgesø; Ulrik Gether; Kristian Strømgaard; Benny Bang-Andersen; Claus J Loland
Journal:  Br J Pharmacol       Date:  2016-02-08       Impact factor: 8.739

5.  Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters.

Authors:  Kasper Severinsen; Johan F Kraft; Heidi Koldsø; Katrine A Vinberg; Richard B Rothman; John S Partilla; Ove Wiborg; Bruce Blough; Birgit Schiøtt; Steffen Sinning
Journal:  ACS Chem Neurosci       Date:  2012-06-10       Impact factor: 4.418

6.  Identification of the benztropine analog [125I]GA II 34 binding site on the human dopamine transporter.

Authors:  Michael J Tomlinson; Danielle Krout; Akula Bala Pramod; John R Lever; Amy Hauck Newman; L Keith Henry; Roxanne A Vaughan
Journal:  Neurochem Int       Date:  2018-08-17       Impact factor: 3.921

Review 7.  Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.

Authors:  Huailing Zhong; Nasser Haddjeri; Connie Sánchez
Journal:  Psychopharmacology (Berl)       Date:  2011-09-08       Impact factor: 4.530

8.  The promiscuity of the dopamine transporter: implications for the kinetic analysis of [3H]serotonin uptake in rat hippocampal and striatal synaptosomes.

Authors:  Seth D Norrholm; David B Horton; Linda P Dwoskin
Journal:  Neuropharmacology       Date:  2007-10-07       Impact factor: 5.250

9.  Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release.

Authors:  Richard B Rothman; Christina M Dersch; Subramaniam Ananthan; John S Partilla
Journal:  J Pharmacol Exp Ther       Date:  2009-02-24       Impact factor: 4.030

Review 10.  A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?

Authors:  Connie Sanchez; Elin H Reines; Stuart A Montgomery
Journal:  Int Clin Psychopharmacol       Date:  2014-07       Impact factor: 1.659

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.